Evidence map›Paper›PMID 32414413›Full record

ArticleAlzheimer's research & therapy2020

Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer's disease and controls.

Helen Zong Ying Wu, Anbupalam Thalamuthu, Lesley Cheng, Christopher Fowler, Colin L Masters, Perminder Sachdev, Karen A Mather, the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. The Role of miR-137 in Neurodegenerative Disorders.International journal of molecular sciences · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Early Diagnosis of Alzheimer's Disease with Blood Test; Tempting but Challenging.International journal of molecular and cellular medicine · 2023
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Helen Zong Ying WuCentre for Healthy Brain and Ageing, University of New South Wales, Sydney, Australia. Helen.Wu@health.nsw.gov.au.ORCID 0000-0003-2201-9848
Anbupalam ThalamuthuCentre for Healthy Brain and Ageing, University of New South Wales, Sydney, Australia.
Lesley ChengDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, Australia.
Christopher FowlerFlorey Institute, University of Melbourne, Melbourne, Australia.
Colin L MastersFlorey Institute, University of Melbourne, Melbourne, Australia.
Perminder SachdevCentre for Healthy Brain and Ageing, University of New South Wales, Sydney, Australia.
Karen A MatherCentre for Healthy Brain and Ageing, University of New South Wales, Sydney, Australia.
the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The University of Melbourne · AUUNSW Sydney · AULa Trobe University · AUNew South Wales Department of Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeripheral blood microRNAs (miRNA) have been identified as potential biomarkers for Alzheimer's disease (AD). Study results have generally been inconsistent and limited by sample heterogeneity. The aim of this study is to establish candidate blood miRNA biomarkers for AD by comparing differences in miRNA expression between participants with brain amyloid imaging-defined AD and normal cognition.

methodsBlood RNA was extracted from a subset of participants from the Australian Imaging Biomarkers Lifestyle Study of Ageing cohort (AIBL) with brain amyloid imaging results. MiRNA profiling was performed using small RNA sequencing on 71 participants, comprising 40 AD with high brain amyloid burden on imaging (amyloid positive) and 31 cognitively normal controls with low brain amyloid burden (amyloid negative). Cross-sectional comparisons were made between groups to examine differential miRNA expression levels using Fisher's exact tests. Replication of results was undertaken using a publicly available dataset of blood miRNA data of AD and controls. In silico analysis of downstream messenger RNA targets of candidate miRNAs was performed to elucidate potential biological function.

resultsAfter quality control, 816 miRNAs were available for analysis. There were 71 significantly differentially expressed miRNAs between the AD and control groups (p < 0.05). Two of these miRNAs, miR-146b-5p and miR-15b-5p, were also significant in the replication cohort. Pathways analysis showed these miRNAs to be involved in innate immune system and regulation of the cell cycle, respectively, both of which have relevance to AD pathogenesis.

conclusionBlood miR-146b-5p and miR15b-5p showed consistent differential expression in AD compared to controls. Further replication and translational studies in strictly phenotyped cohorts are needed to establish their role as biomarkers for AD to have clinical utility.

Indexed as

Alzheimer DiseaseMicroRNAsAustraliaBiomarkersBrainCross-Sectional StudiesHumansBiomarkersMicroRNAsAlzheimer’s diseaseAmyloid imagingBiomarkerEarly diagnosisMicroRNA

Identifiers

PMID32414413
PMCPMC7229622
OpenAlexW3026205487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.